Moleculin Biotech's total assets for Q3 2025 were $20.35M, a decrease of -5.74% from the previous quarter. MBRX total liabilities were $47.27M for the fiscal quarter, a 64.38% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.